Artemisia argyi extracts overcome lapatinib resistance via enhancing TMPRSS2 activation in HER2 ‐positive breast cancer
Environmental Toxicology · 2024
DOI: 10.1002/tox.24202 ↗Kurz gefasst
Fachartikel in der Zeitschrift Environmental Toxicology, 2024. Verfasst von Chien-Yi Ho und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan. Hauptthemen laut MEDLINE: Lapatinib, Breast Neoplasms, Drug Resistance, Neoplasm, Artemisia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: China Medical University Hsin-Chu Hospital, Hsinchu, Taiwan.
Abstract (Originalsprache)
Breast cancer stands as the predominant malignancy and primary cause of cancer‐related mortality among females globally. Approximately 25% of breast cancers exhibit HER2 overexpression, imparting a more aggressive tumor phenotype and correlating with poor prognoses. Patients with metastatic breast cancer receiving HER2 tyrosine kinase inhibitors (HER2 TKIs), such as Lapatinib, develop acquired resistance within a year, posing a critical challenge in managing this disease. Here, we explore the potential of Artemisia argyi , a Chinese herbal medicine known for its anti‐cancer properties, in mitigating HER2 TKI resistance in breast cancer. Analysis of the Cancer Genome Atlas (TCGA) revealed diminished expression of transmembrane serine protease 2 (TMPRSS2), a subfamily of membrane proteolytic enzymes, in breast cancer patients, correlating with unfavorable outcomes. Intriguingly, lapatinib‐responsive patients exhibited higher TMPRSS2 expression. Our study unveiled that the compounds from Artemisia argyi , eriodictyol, and umbelliferone could inhibit the growth of lapatinib‐resistant HER2‐positive breast cancer cells. Mechanistically, they suppressed HER2 kinase activation by enhancing TMPRSS2 activity. Our findings propose TMPRSS2 as a critical determinant in lapatinib sensitivity, and Artemisia argyi emerges as a potential agent to overcome lapatinib via activating TMPRSS2 in HER2‐positive breast cancer. This study not only unravels the molecular mechanisms driving cell death in HER2‐positive breast cancer cells induced by Artemisia argyi but also lays the groundwork for developing novel inhibitors to enhance therapy outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan.
- Division of Family Medicine, Physical Examination Center, China Medical University Hsinchu Hospital, Hsinchu, Taiwan.
- Department of Medical Research, China Medical University Hsinchu Hospital, Hsinchu, Taiwan.
- Graduate Institute of Biomedical Science, China Medical University, Taichung, Taiwan.
- Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan.
- School of Chinese Medicine, China Medical University, Taichung, Taiwan.
ORCID-Profile: Wei-Chien Huang
Förderung
- China Medical University Hsin-Chu Hospital, Hsinchu, Taiwan
Zitieren
APA
Ho, C. Y., Wei, C. Y., Zhao, R. W., Ye, Y. L., Huang, H. C., Lee, J. C., Cheng, F. J., & Huang, W. C. (2024). Artemisia argyi extracts overcome lapatinib resistance via enhancing TMPRSS2 activation in HER2 ‐positive breast cancer. Environmental Toxicology. https://doi.org/10.1002/tox.24202
Vancouver
Ho CY, Wei CY, Zhao RW, Ye YL, Huang HC, Lee JC, et al. Artemisia argyi extracts overcome lapatinib resistance via enhancing TMPRSS2 activation in HER2 ‐positive breast cancer. Environmental Toxicology. 2024. doi:10.1002/tox.24202
BibTeX
@article{Ho2024,
author = {Ho, Chien-Yi and Wei, Cheng-Yen and Zhao, Ruo-Wen and Ye, Yi-Lun and Huang, Hui-Chi and Lee, Jen-Chih and Cheng, Fang-Ju and Huang, Wei-Chien},
title = {Artemisia argyi extracts overcome lapatinib resistance via enhancing TMPRSS2 activation in HER2 ‐positive breast cancer},
journal = {Environmental Toxicology},
year = {2024},
doi = {10.1002/tox.24202}
}
EUVIMED